Chapter 40 Immunocompromised Host
1 What is the initial approach to the immunocompromised host in the intensive care unit (ICU)?
The approach in the ICU setting relies on several factors:
High index of clinical suspicion: Immune-compromised hosts often have atypical presentations of infection. For example, patients with severe immunocompromise may lack fever or abscess formation.
Understanding of the host’s immune defect: Recognizing the deficient pathway (cell mediated vs. humoral) enables the physician to expand the differential diagnosis and has implications for empiric therapy.
Aggressive diagnostics: Blood work and cultures, imaging, bronchoscopy, and tissue biopsy, if indicated, are all essential in the initial work-up of a suspected infection.
Early appropriate antimicrobial therapy: This is key when dealing with infections in the immunocompromised patient.
2 What is the “net state of immunosuppression,” and why is it important?
Immunosuppressive medications. The degree of immunosuppression conferred by these medications will be influenced by their type, dose, and duration of therapy.
Presence of leukopenia. Long-standing neutropenia carries a different risk of infection as compared with acute-onset neutropenia. For example, acute neutropenia conveys an increased risk of infections with gram-negative and enteric organisms. As the duration of neutropenia continues, these patients are at increasing risk for invasive fungal infections.
Metabolic factors. Poor nutrition, hyperglycemia, and uremia all confer an increased risk for infection.
Concurrent infection with immunomodulating viruses such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), hepatitis B and C, human herpes virus 6 (HHV-6), and HIV. These infections can weaken the host’s defenses either by a low level of viral replication or by reducing the function of infected white blood cells. This leads to an increased risk for bacterial or fungal infection.
Anatomic factors. The presence of obstructing tumors, stents, central venous catheters, and endotracheal tubes can affect a host’s risk for infection.
3 How is immunosuppression measured?
Assessment can be based on the following:
Duration and level of neutropenia in those undergoing cytotoxic chemotherapy are used to determine the risk of infection and need for empiric antibiotic therapy. For example, patients with a longer duration of absolute neutropenia have a greater risk for invasive fungal infection compared with patients with acute neutropenia.
CD4 cell count in patients with HIV is an accurate measure of their immune function. A patient with HIV who has an absolute CD4 count of 700/mm3 has a very different infection risk compared with someone whose CD4 counts are under 100/mm3.
Treatment, type, and duration of therapy in patients receiving immunosuppression after solid organ, stem cell, or bone marrow transplantation (BMT). Also, the type of transplant (matched or unmatched donor) may be important. Patients who undergo stem cell transplantation or BMT from an allogeneic human leukocyte antigen–identical sibling or matched unrelated donor are at greatest risk for infection because they may require more immunosuppression.
4 Do certain immunosuppressive therapies carry a specific risk of infection?
Agent | Mechanism of action | Associated risk of infection |
---|---|---|
Corticosteroids | Down-regulates lymphocyte and macrophage function Interferes with inflammatory response |
Long-term use—PCP, hepatitis B, bacterial, molds, mycobacterial disease Bolus use—CMV, BK virus nephropathy |
Calcineurin inhibitors |
Bacterial and fungal infections
Decreases IL-2
Hepatitis B reactivation
Lymphoma
IL, Interleukin; TNF, tumor necrosis factor; VZV, varicella-zoster virus.
* Immunosuppression is greater when used as a bolus for antirejection rather than when used as initial induction therapy.
Modified from Fishman JA, Issa NC: Infections in organ transplantation: risk factors and evolving patterns of infection. Infect Dis Clin North Am 24:273-283, 2010, and Danovitch G: Immunosuppressive medications and protocols for kidney transplantation. In Danovitch G (ed): Handbook of Kidney Transplantation. Philadelphia, Lippincott Williams & Wilkins, 2004, pp 72-134.
5 How does the timing of solid organ transplantation affect a patient’s risk for infection?
Months after transplantation | Type of infection |
---|---|
0-1 | Hospital Derived
Donor-Derived Infections |
Reactivation of Latent Recipient Infections
Reactivation of Latent Donor Derived
Fungal Infections
Atypical Bacterial
Late Viral Infections
VZV, Varicella-zoster virus.
* Generally thought to be the time of greatest immunosuppression.
Modified from Fishman J: Infection in solid organ transplant recipients. N Engl J Med 357:2601-2614, 2007, and Syndman DR: Epidemiology of infections after solid-organ transplantation. Clin Infect Dis 33(Suppl 1):S5, 2001.
7 What is the initial recommended work-up of suspected infection in the immunocompromised host?
Questions that may provide clinical clues to source of infection:
Type and duration of immunosuppressive medication
Duration of time since transplantation
Sick exposures: family members, co-workers
Recent travel, both in and outside of the country
Eating habits: raw fish, game meat
Hobbies: hunting, fishing, gardening
History of tuberculosis exposure
Use of antimicrobial prophylaxis for viral or bacterial infection